The novel MEK inhibitor atebimetinib in combination with modified gemcitabine/nab-paclitaxel led to a 12-month overall ...

A former prostate cancer patient who got the all-clear said taking part in a trial that cut his radiotherapy treatments ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

In prostate cancer, hormone therapy is treatment to keep the cancer cells from getting testosterone, the main male hormone (androgen). Hormone therapy for prostate cancer is also called ...

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...

Cardiovascular (CV) disease is a leading cause of death among patients with prostate cancer. | Cardiovascular (CV) disease is ...

Scientists at EPFL and Johns Hopkins uncover the central role of an enzyme in controlling prostate cancer subtypes and ...

Prostate cancer is one of the most common cancers in men but often goes unnoticed. Experts stress early screening, awareness ...

Foresee Pharmaceuticals has shown that a long-acting version of its injectable prostate cancer med Camcevi can help patients ...